Carter Center Guinea worm eradication program in 'final stages'

NewsGuard 100/100 Score

"Former U.S. President Jimmy Carter announced today that the international Guinea worm eradication campaign spearheaded by the Carter Center has reached its final stages with only 542 cases reported worldwide in 2012," a Carter Center press release reports, noting the provisional case numbers show cases of the disease were halved in 2012 in the four remaining endemic countries. "In 2012, South Sudan reported the majority of cases (521) from a handful of isolated locations. The remaining cases in 2012 were reported by Chad (10), Mali (7), and Ethiopia (4)," the press release notes. "The collateral impact of this campaign is immense; it empowers people in some of the world's most neglected communities to protect themselves from a terrible disease and to believe in the possibility of a brighter future," President Carter said in the press release, adding, "We are so close and I look forward to personally announcing that we have stopped transmission of Guinea worm disease worldwide" (1/17).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.